Stocks · News reference

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

Aug 5, 2026, 5:06 PMBenzinga Newsdesk

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $141 to $155.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 5, 2026, 5:06 PM
Checked: Aug 5, 2026, 5:06 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 28, 2026, 12:58 PMBenzinga Newsdesk
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120
Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.
RYTM
BenzingaAug 24, 2026, 12:02 PMBenzinga Newsdesk
Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health To Treat Acquired Hypothalamic Obesity
RYTM
BenzingaAug 12, 2026, 5:18 PMVandana Singh
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesity in adults and children 4 and older.
RYTM
BenzingaAug 11, 2026, 12:03 PMBenzinga Newsdesk
Rhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug Designation
RYTM